Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KDM4A | O75164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 3/20 | 0.44 |
| ▸ | GABRD | O14764 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31690020 | 0.90 | NAPRT (0.46) | NAPRTNOS3NOS2KDM4EKMT2A | |
| SCHEMBL5169967 | 0.84 | NOS3 (0.52) | NAPRTNOS3NOS2KDM4EKMT2A | |
| SCHEMBL3553958 | 0.79 | KDM4E (0.53) | NOS3NOS2KDM4EALDH1A1MAPT | |
| SCHEMBL14335806 | 0.79 | KDM4E (0.52) | NAPRTKDM4EKMT2ATDP1L3MBTL1 | |
| SCHEMBL353106 | 0.79 | KDM4E (0.47) | NAPRTKDM4EKMT2ATDP1L3MBTL1 | |
| SCHEMBL18226305 | 0.79 | NAPRT (0.59) | NAPRTNOS3NOS2KDM4EKMT2A | |
| SCHEMBL31661247 | 0.78 | NOS2 (0.46) | NAPRTNOS3NOS2KMT2A | |
| Hydrochloric Acid SCHEMBL18226370 | 0.78 | NAPRT (0.57) | NAPRTNOS3NOS2KDM4EKMT2A | |
| SCHEMBL1767848 | 0.78 | KDM4E (0.46) | NAPRTKDM4EKMT2ATDP1L3MBTL1 | |
| SCHEMBL19857454 | 0.78 | NAPRT (0.57) | NAPRTKDM4EKMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126345-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-02-08 | — | — | EP | claimed |
| WO-2015153498-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS, APS (DK) | 2015-10-08 | — | — | WO | claimed |
| EP-4624465-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024111560-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | 日本新薬株式会社 | 2024-05-30 | — | — | WO | disclosed |
| US-11731954-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RES INC (US) | 2023-08-22 | — | — | US | disclosed |
| CN-108892661-B | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-3697785-B1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11426412-B2 | Imidazo-pyridine compounds as PAD inhibitors | Jubilant Epipad LLC (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-11001568-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| WO-2020216669-A1 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| WO-2010104899-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010051926-A2 | NEW HALOGEN-SUBSTITUTED BONDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| WO-2010038086-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001568-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | NAPRT 1299/4885NOS3 2126/4885NOS2 2688/4885 |
| US-11731954-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | NAPRT 1299/4885NOS3 2126/4885NOS2 2688/4885 |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | NAPRT 671/4885NOS3 4242/4885NOS2 4368/4885 |
| US-11426412-B2 | Imidazo-pyridine compounds as PAD inhibitors | PADI4, PADI1, PADI2 | NAPRT 664/4885NOS3 777/4885NOS2 1215/4885 |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, BMI1 | NAPRT 1299/4885NOS3 2126/4885NOS2 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.